Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 09, 2021 Filed Aug 10, 2021 15:58 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
Exercise / conversionBio-Rad A Common Stock | 3,000 | $139.56 | $418,680.00 |
DisclosureSEC source: 0001062993-21-007240 · form4.xml · nonDerivative · entry 1 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 16:40 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
SaleBio-Rad A Common Stock | 327 | $760.26 | $248,605.02 |
DisclosureSEC source: 0001062993-21-007080 · form4.xml · nonDerivative · entry 1 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 919.0531 F1 · balance_after: Includes 13.1255 and 12.9276 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 03/31/2021 and 06/30/2021, respectively. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 16:38 UTC |
Daskal IlanEVP, Chief Financial Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,400 | $0.00 Strike: $309.84 | $0.00 |
DisclosureSEC source: 0001062993-21-007078 · form4.xml · derivative · entry 5 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,100 Underlying: Bio-Rad A Common Stock · 1,400 shares Expires 2029-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing a right to purchase a total of 3,500 shares, became exercisable in five equal annual installments beginning on April 8, 2020, which was the first anniversary of the date on which the option was granted. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 16:38 UTC |
Daskal IlanEVP, Chief Financial Officer
|
SaleBio-Rad A Common Stock | 489 | $753.32 | $368,373.48 |
DisclosureSEC source: 0001062993-21-007078 · form4.xml · nonDerivative · entry 4 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $753.28 to $753.40, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 16:38 UTC |
Daskal IlanEVP, Chief Financial Officer
|
SaleBio-Rad A Common Stock | 954 | $751.98 | $717,388.92 |
DisclosureSEC source: 0001062993-21-007078 · form4.xml · nonDerivative · entry 3 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 496 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $751.98 to $752.22, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 16:38 UTC |
Daskal IlanEVP, Chief Financial Officer
|
SaleBio-Rad A Common Stock | 857 | $750.85 | $643,478.45 |
DisclosureSEC source: 0001062993-21-007078 · form4.xml · nonDerivative · entry 2 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,450 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $750.77 to $751.39, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 16:38 UTC |
Daskal IlanEVP, Chief Financial Officer
|
Exercise / conversionBio-Rad A Common Stock | 1,400 | $309.84 | $433,776.00 |
DisclosureSEC source: 0001062993-21-007078 · form4.xml · nonDerivative · entry 1 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2021 Filed Apr 30, 2021 18:31 UTC |
Last Andrew J.EVP, Chief Operating Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 1,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-003968 · form4.xml · derivative · entry 3 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Bio-Rad A Common Stock · 1,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: On April 29, 2019, the reporting person was granted 5,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On April 29, 2019, the reporting person was granted 5,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| April 29, 2021 Filed Apr 30, 2021 18:31 UTC |
Last Andrew J.EVP, Chief Operating Officer
|
Tax withholdingBio-Rad A Common Stock | 466 | $640.73 | $298,580.18 |
DisclosureSEC source: 0001062993-21-003968 · form4.xml · nonDerivative · entry 2 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,267.9903 Read SEC document |
| April 29, 2021 Filed Apr 30, 2021 18:31 UTC |
Last Andrew J.EVP, Chief Operating Officer
|
Exercise / conversionBio-Rad A Common Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-003968 · form4.xml · nonDerivative · entry 1 Last Andrew J. · CIK 0001485088 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,733.9903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. F2 · balance_after: Includes 16.5639 and 14.1410 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 09/30/2020 and 03/31/2021, respectively. Read SEC document |
| April 29, 2021 Filed May 3, 2021 17:48 UTC |
RAMALINGAM AJITSVP, Chief Accounting Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 276 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-004022 · form4.xml · derivative · entry 3 RAMALINGAM AJIT · CIK 0001807891 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,108 Underlying: Bio-Rad A Common Stock · 276 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: On April 29, 2020, the reporting person was granted 1,384 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On April 29, 2020, the reporting person was granted 1,384 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| April 29, 2021 Filed May 3, 2021 17:48 UTC |
RAMALINGAM AJITSVP, Chief Accounting Officer
|
Tax withholdingBio-Rad A Common Stock | 96 | $640.73 | $61,510.08 |
DisclosureSEC source: 0001062993-21-004022 · form4.xml · nonDerivative · entry 2 RAMALINGAM AJIT · CIK 0001807891 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221.6638 Read SEC document |
| April 29, 2021 Filed May 3, 2021 17:48 UTC |
RAMALINGAM AJITSVP, Chief Accounting Officer
|
Exercise / conversionBio-Rad A Common Stock | 276 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-004022 · form4.xml · nonDerivative · entry 1 RAMALINGAM AJIT · CIK 0001807891 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317.6638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. F2 · balance_after: Includes 16.3100, 14.2312 and 11.1226 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 09/30/2020, 12/31/2020, and 03/31/2021, respectively. Read SEC document |
| April 08, 2021 Filed Apr 9, 2021 15:38 UTC |
Daskal IlanEVP, Chief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 700 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-003522 · form4.xml · derivative · entry 3 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,100 Underlying: Bio-Rad A Common Stock · 700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: On April 8, 2019, the reporting person was granted 3,500 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On April 8, 2019, the reporting person was granted 3,500 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| April 08, 2021 Filed Apr 9, 2021 15:38 UTC |
Daskal IlanEVP, Chief Financial Officer
|
Tax withholdingBio-Rad A Common Stock | 250 | $592.23 | $148,057.50 |
DisclosureSEC source: 0001062993-21-003522 · form4.xml · nonDerivative · entry 2 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 907 Read SEC document |
| April 08, 2021 Filed Apr 9, 2021 15:38 UTC |
Daskal IlanEVP, Chief Financial Officer
|
Exercise / conversionBio-Rad A Common Stock | 700 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-003522 · form4.xml · nonDerivative · entry 1 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 21:05 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 400 | $0.00 Strike: $159.32 | $0.00 |
DisclosureSEC source: 0001062993-21-001838 · form4.xml · derivative · entry 5 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 850 Underlying: Bio-Rad A Common Stock · 400 shares Expires 2026-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option, representing a right to purchase a total of 2,500 shares, became exercisable in five equal annual installments beginning on September 7, 2017, which was the first anniversary of the date on which the option was granted. Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 21:05 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
SaleBio-Rad A Common Stock | 196.107 | $640.17 | $125,541.82 |
DisclosureSEC source: 0001062993-21-001838 · form4.xml · nonDerivative · entry 4 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,220 Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 21:05 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
SaleBio-Rad A Common Stock | 327 | $640.92 | $209,580.84 |
DisclosureSEC source: 0001062993-21-001838 · form4.xml · nonDerivative · entry 3 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,416.107 Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 21:05 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
SaleBio-Rad A Common Stock | 400 | $640.94 | $256,376.00 |
DisclosureSEC source: 0001062993-21-001838 · form4.xml · nonDerivative · entry 2 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,743.107 Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 21:05 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
Exercise / conversionBio-Rad A Common Stock | 400 | $159.32 | $63,728.00 |
DisclosureSEC source: 0001062993-21-001838 · form4.xml · nonDerivative · entry 1 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,143.107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 19.6358 and 0.6743 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 09/30/2020 and 12/31/2020, respectively. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:34 UTC |
WRIGHT DARAExecutive Vice President
|
Exercise / conversionRestricted Stock Units · Derivative | 502 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-20-006429 · form4.xml · derivative · entry 3 WRIGHT DARA · CIK 0001796980 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,009 Underlying: Bio-Rad A Common Stock · 502 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: On December 16, 2019, the reporting person was granted 2,511 restricted stock units, vesting in 5 equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On December 16, 2019, the reporting person was granted 2,511 restricted stock units, vesting in 5 equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:34 UTC |
WRIGHT DARAExecutive Vice President
|
Tax withholdingBio-Rad A Common Stock | 174 | $576.72 | $100,349.28 |
DisclosureSEC source: 0001062993-20-006429 · form4.xml · nonDerivative · entry 2 WRIGHT DARA · CIK 0001796980 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328 Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:34 UTC |
WRIGHT DARAExecutive Vice President
|
Exercise / conversionBio-Rad A Common Stock | 502 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-20-006429 · form4.xml · nonDerivative · entry 1 WRIGHT DARA · CIK 0001796980 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 17:54 UTC |
Crowley MichaelEVP, GBL Commercial Operations
|
SaleBio-Rad A Common Stock | 374 | $580.67 | $217,170.58 |
DisclosureSEC source: 0001062993-20-006420 · form4.xml · nonDerivative · entry 1 Crowley Michael · CIK 0001629381 · EVP, GBL Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,669 Read SEC document |
| December 07, 2020 Filed Dec 14, 2020 18:09 UTC |
SCHWARTZ ALICE NDirector · 10% owner
|
GiftBio-Rad A Common Stock | 1,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-20-006296 · form4.xml · nonDerivative · entry 1 SCHWARTZ ALICE N · CIK 0001248076 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Alice N. Schwartz Revocable Trust Disclosed balance after: 1,791,821 Read SEC document |
| December 07, 2020 Filed Dec 21, 2020 16:08 UTC Amendment |
SCHWARTZ ALICE NDirector · 10% owner
|
GiftBio-Rad A Common Stock | 1,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-20-006501 · form4a.xml · nonDerivative · entry 1 SCHWARTZ ALICE N · CIK 0001248076 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Alice N. Schwartz Revocable Trust Disclosed balance after: 1,791,821 F1 · shares: The Form 4 is being amended only to add the reporting person's name on the signature line. Read SEC document |
| December 04, 2020 Filed Dec 14, 2020 18:09 UTC |
SCHWARTZ ALICE NDirector · 10% owner
|
GiftBio-Rad B Common Stock | 162 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-20-006296 · form4.xml · nonDerivative · entry 6 SCHWARTZ ALICE N · CIK 0001248076 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Alice N. Schwartz Revocable Trust Disclosed balance after: 438,518 Read SEC document |
| December 04, 2020 Filed Dec 17, 2020 00:29 UTC Amendment |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
GiftBio-Rad B Common Stock | 27 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-20-006406 · form4a.xml · nonDerivative · entry 3 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 12,838 F1 · shares: The Form 4 is being amended only to add the reporting person's name on the signature line. F2 · ownership.nature: The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| December 04, 2020 Filed Dec 17, 2020 00:29 UTC Amendment |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
GiftBio-Rad B Common Stock | 27 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-20-006406 · form4a.xml · nonDerivative · entry 2 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,274 F1 · shares: The Form 4 is being amended only to add the reporting person's name on the signature line. Read SEC document |
| December 04, 2020 Filed Dec 16, 2020 17:55 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
GiftBio-Rad B Common Stock | 27 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-20-006381 · form4.xml · nonDerivative · entry 3 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 12,838 F1 · ownership.nature: The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| December 04, 2020 Filed Dec 16, 2020 17:55 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
GiftBio-Rad B Common Stock | 27 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-20-006381 · form4.xml · nonDerivative · entry 2 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,274 Read SEC document |
| December 04, 2020 Filed Dec 18, 2020 00:50 UTC |
SCHWARTZ STEVEN D10% owner
|
GiftBio-Rad B Common Stock | 27 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-20-006438 · form4.xml · nonDerivative · entry 4 SCHWARTZ STEVEN D · CIK 0000940804 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 12,838 F1 · ownership.nature: The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| December 04, 2020 Filed Dec 18, 2020 00:50 UTC |
SCHWARTZ STEVEN D10% owner
|
GiftBio-Rad B Common Stock | 27 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-20-006438 · form4.xml · nonDerivative · entry 3 SCHWARTZ STEVEN D · CIK 0000940804 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,066 Read SEC document |
| December 04, 2020 Filed Dec 21, 2020 16:08 UTC Amendment |
SCHWARTZ ALICE NDirector · 10% owner
|
GiftBio-Rad B Common Stock | 162 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-20-006501 · form4a.xml · nonDerivative · entry 6 SCHWARTZ ALICE N · CIK 0001248076 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Alice N. Schwartz Revocable Trust Disclosed balance after: 438,518 F1 · shares: The Form 4 is being amended only to add the reporting person's name on the signature line. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 17:40 UTC |
TUMOLO ANNETTEExecutive Vice President
|
GiftBio-Rad A Common Stock | 423 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-20-005478 · form4.xml · nonDerivative · entry 5 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,699.3476 Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 17:40 UTC |
TUMOLO ANNETTEExecutive Vice President
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,200 | $0.00 Strike: $159.32 | $0.00 |
DisclosureSEC source: 0001062993-20-005478 · form4.xml · derivative · entry 6 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Underlying: Bio-Rad A Common Stock · 1,200 shares Expires 2026-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 7, 2017, which was the first anniversary of the date on which the option was granted. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 17:40 UTC |
TUMOLO ANNETTEExecutive Vice President
|
SaleBio-Rad A Common Stock | 246 | $641.53 | $157,816.38 |
DisclosureSEC source: 0001062993-20-005478 · form4.xml · nonDerivative · entry 4 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,122.3476 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $641.50 to $641.92, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 17:40 UTC |
TUMOLO ANNETTEExecutive Vice President
|
SaleBio-Rad A Common Stock | 734 | $640.78 | $470,332.52 |
DisclosureSEC source: 0001062993-20-005478 · form4.xml · nonDerivative · entry 3 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,368.3476 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $640.24 to $641.19, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 17:40 UTC |
TUMOLO ANNETTEExecutive Vice President
|
SaleBio-Rad A Common Stock | 220 | $639.62 | $140,716.40 |
DisclosureSEC source: 0001062993-20-005478 · form4.xml · nonDerivative · entry 2 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,102.3476 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $639.16 to $640.14, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 17:40 UTC |
TUMOLO ANNETTEExecutive Vice President
|
Exercise / conversionBio-Rad A Common Stock | 1,200 | $159.32 | $191,184.00 |
DisclosureSEC source: 0001062993-20-005478 · form4.xml · nonDerivative · entry 1 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,322.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 11, 2020 Filed Sep 14, 2020 22:59 UTC |
HUTTON RONALD WVice President and Treasurer
|
Exercise / conversionRestricted Stock Units · Derivative | 150 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001812865-20-000049 · edgar.xml · derivative · entry 3 HUTTON RONALD W · CIK 0001248073 · Vice President and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 11, 2016. F3 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 11, 2016. Read SEC document |
| September 11, 2020 Filed Sep 14, 2020 22:59 UTC |
HUTTON RONALD WVice President and Treasurer
|
Tax withholdingBio-Rad A Common Stock | 52 | $505.02 | $26,261.04 |
DisclosureSEC source: 0001812865-20-000049 · edgar.xml · nonDerivative · entry 2 HUTTON RONALD W · CIK 0001248073 · Vice President and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,688.2875 Read SEC document |
| September 11, 2020 Filed Sep 14, 2020 22:59 UTC |
HUTTON RONALD WVice President and Treasurer
|
Exercise / conversionBio-Rad A Common Stock | 150 | $0.00 | $0.00 |
DisclosureSEC source: 0001812865-20-000049 · edgar.xml · nonDerivative · entry 1 HUTTON RONALD W · CIK 0001248073 · Vice President and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,740.2875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 11, 2020 Filed Sep 14, 2020 22:55 UTC |
TUMOLO ANNETTEExecutive Vice President
|
Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001812865-20-000047 · edgar.xml · derivative · entry 3 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning September 11, 2016. F3 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning September 11, 2016. Read SEC document |
| September 11, 2020 Filed Sep 14, 2020 22:55 UTC |
TUMOLO ANNETTEExecutive Vice President
|
Tax withholdingBio-Rad A Common Stock | 298 | $505.02 | $150,495.96 |
DisclosureSEC source: 0001812865-20-000047 · edgar.xml · nonDerivative · entry 2 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,122.3476 Read SEC document |
| September 11, 2020 Filed Sep 14, 2020 22:55 UTC |
TUMOLO ANNETTEExecutive Vice President
|
Exercise / conversionBio-Rad A Common Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001812865-20-000047 · edgar.xml · nonDerivative · entry 1 TUMOLO ANNETTE · CIK 0001717996 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,420.3476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 11, 2020 Filed Sep 14, 2020 15:42 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001812865-20-000043 · edgar.xml · derivative · entry 18 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F8 · derivative.exercise_date: The restricted stock units vest in five equal annual installments beginning on September 11, 2016. F8 · derivative.expiration_date: The restricted stock units vest in five equal annual installments beginning on September 11, 2016. Read SEC document |
| September 11, 2020 Filed Sep 14, 2020 15:42 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 500 | $0.00 Strike: $139.56 | $0.00 |
DisclosureSEC source: 0001812865-20-000043 · edgar.xml · derivative · entry 17 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 500 shares Expires 2025-09-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests in five equal annual installments beginning on September 11, 2016. Read SEC document |
| September 11, 2020 Filed Sep 14, 2020 15:42 UTC |
Magni GiovanniEVP, Chief Strategy Officer
|
Tax withholdingBio-Rad A Common Stock | 248 | $505.02 | $125,244.96 |
DisclosureSEC source: 0001812865-20-000043 · edgar.xml · nonDerivative · entry 12 Magni Giovanni · CIK 0001292816 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,495 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.